Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants

被引:49
作者
DeVincenzo, JP
Hall, CB
Kimberlin, DW
Sánchez, PJ
Rodriguez, WJ
Jantausch, BA
Corey, L
Kahn, JS
Englund, JA
Suzich, JA
Palmer-Hill, FJ
Branco, L
Johnson, S
Patel, NK
Piazza, FM
机构
[1] Univ Tennessee, Lebonheur Childrens Med Ctr, Memphis, TN 38103 USA
[2] Childrens Fdn Res Ctr, Memphis, TN USA
[3] Univ Rochester, Rochester, NY USA
[4] Univ Alabama, Birmingham, AL USA
[5] Univ Texas, SW Med Ctr Dallas, Dallas, TX 75235 USA
[6] Childrens Natl Med Ctr, Washington, DC 20010 USA
[7] Univ Washington, Seattle, WA 98195 USA
[8] Yale Univ, New Haven, CT USA
[9] Univ Chicago, Chicago, IL 60637 USA
[10] MedImmune, Gaithersburg, MD USA
关键词
D O I
10.1086/423213
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab ( Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.
引用
收藏
页码:975 / 978
页数:4
相关论文
共 8 条
  • [1] MICRONEUTRALIZATION TEST FOR RESPIRATORY SYNCYTIAL VIRUS BASED ON AN ENZYME-IMMUNOASSAY
    ANDERSON, LJ
    HIERHOLZER, JC
    BINGHAM, PG
    STONE, YO
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1985, 22 (06) : 1050 - 1052
  • [2] CHARACTERIZATION OF 2 ANTIGENIC SITES RECOGNIZED BY NEUTRALIZING MONOCLONAL-ANTIBODIES DIRECTED AGAINST THE FUSION GLYCOPROTEIN OF HUMAN RESPIRATORY SYNCYTIAL VIRUS
    ARBIZA, J
    TAYLOR, G
    LOPEZ, JA
    FURZE, J
    WYLD, S
    WHYTE, P
    STOTT, EJ
    WERTZ, G
    SULLENDER, W
    TRUDEL, M
    MELERO, JA
    [J]. JOURNAL OF GENERAL VIROLOGY, 1992, 73 : 2225 - 2234
  • [3] NEUTRALIZATION EPITOPES OF THE F-GLYCOPROTEIN OF RESPIRATORY SYNCYTIAL VIRUS - EFFECT OF MUTATION UPON FUSION FUNCTION
    BEELER, JA
    COELINGH, KV
    [J]. JOURNAL OF VIROLOGY, 1989, 63 (07) : 2941 - 2950
  • [4] Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody
    DeVincenzo, JP
    Aitken, J
    Harrison, U
    [J]. JOURNAL OF PEDIATRICS, 2003, 143 (01) : 123 - 126
  • [5] Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease
    Feltes, TF
    Cabalka, AK
    Meissner, C
    Piazza, FM
    Carlin, DA
    Top, FH
    Connor, EM
    Sondheimer, HM
    [J]. JOURNAL OF PEDIATRICS, 2003, 143 (04) : 532 - 540
  • [6] Medical progress - Respiratory syncytial virus and parainfluenza virus.
    Hall, CB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) : 1917 - 1928
  • [7] Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus
    Johnson, S
    Oliver, C
    Prince, GA
    Hemming, VG
    Pfarr, DS
    Wang, SC
    Dormitzer, M
    OGrady, J
    Koenig, S
    Tamura, JK
    Woods, R
    Bansal, G
    Couchenour, D
    Tsao, E
    Hall, WC
    Young, JF
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 176 (05) : 1215 - 1224
  • [8] Null D, 1998, PEDIATRICS, V102, P531, DOI 10.1542/peds.102.3.531